On April 19, 2026, UBS has started coverage of Amneal Pharmaceuticals AMRX with a Buy rating and a price target of $19, citing its strong growth potential in the specialty pharmaceuticals sector. After a 14% decline in shares over the last two months, UBS considers this an opportune moment for investors.
The initiation of coverage by UBS highlights Amneal Pharmaceuticals' potential for growth, particularly in its specialty pharmaceuticals segment. Analysts project a compound annual growth rate (CAGR) of 6% for this segment from 2025 to 2030, outpacing the broader market consensus of 4%. Key products driving this growth include Crexont, a treatment for Parkinson's disease, and Brekiya, a newly launched migraine therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.